Our results suggest that, despite the low number of cases analyzed, CDKN2A/B deletions are markers of poor survival in B-other ALL, and the association between CDKN2A/B and IKZF1 deletions might also contribute to the dismal prognosis of BCR-ABL1-like. This evidence concerns the gene IKZF1 and acute lymphoblastic leukemia.